← All trials
NCT06216132
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2024
- Primary completion
- Aug 17, 2025
- Completion date
- Nov 11, 2025
- First posted
- Jan 22, 2024
- Last posted
- Jul 8, 2024
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Drug Delivery International LtdLead sponsor
- LabCorpCollaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- Cognitive Research CorporationCollaborator
- CenExel iResearch, LLCOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.